BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35600178)

  • 1. Immunohistochemical expression of transcription factors PAX5, OCT2, BCL6 and transcription regulator P53 in Non-Hodgkin lymphomas: A diagnostic cross-sectional study.
    Ismail S; Elshimali Y; Daoud A; Alshehabi Z
    Ann Med Surg (Lond); 2022 Jun; 78():103786. PubMed ID: 35600178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oct2 and Bob1 are sensitive and specific markers in lineage determination of B cell lymphomas with no expression of conventional B cell markers.
    Yin L; Xu J; Li M; Reddy V; Zhou Q; Liu H; Chu P; Zhang Q; Huang Q; Gao Z; Liang X; Wang HY; Pan Z
    Histopathology; 2016 Nov; 69(5):775-783. PubMed ID: 27319306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
    Wang J; Young L; Win W; Taylor CR
    Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):323-32. PubMed ID: 16280661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas.
    Moore EM; Swerdlow SH; Gibson SE
    Am J Surg Pathol; 2018 Mar; 42(3):342-350. PubMed ID: 29309299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of octamer-binding transcription factors Oct2 and Oct1 and their coactivator BOB.1/OBF.1 in lymphomas.
    Sáez AI; Artiga MJ; Sánchez-Beato M; Sánchez-Verde L; García JF; Camacho FI; Franco R; Piris MA
    Mod Pathol; 2002 Mar; 15(3):211-20. PubMed ID: 11904338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Utility of PAX5 in Hodgkin and Non-Hodgkin Lymphoma: A Study from Northern India.
    Johri N; Patne SC; Tewari M; Kumar M
    J Clin Diagn Res; 2016 Aug; 10(8):XC04-XC07. PubMed ID: 27656544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma.
    Omodei D; Acampora D; Russo F; De Filippi R; Severino V; Di Francia R; Frigeri F; Mancuso P; De Chiara A; Pinto A; Casola S; Simeone A
    Am J Pathol; 2009 Dec; 175(6):2609-17. PubMed ID: 19893048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B- and B-cell marker.
    Willmann M; Müllauer L; Guija de Arespacochaga A; Reifinger M; Mosberger I; Thalhammer JG
    Vet Immunol Immunopathol; 2009 Apr; 128(4):359-65. PubMed ID: 19100628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas.
    Loddenkemper C; Anagnostopoulos I; Hummel M; Jöhrens-Leder K; Foss HD; Jundt F; Wirth T; Dörken B; Stein H
    J Pathol; 2004 Jan; 202(1):60-9. PubMed ID: 14694522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators.
    Cho RJ; McCalmont TH; Ai WZ; Fox LP; Treseler P; Pincus LB
    J Cutan Pathol; 2012 Jun; 39(6):651-8. PubMed ID: 22324490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology.
    Carbone A; Gloghini A; Aiello A; Testi A; Cabras A
    Hum Pathol; 2010 May; 41(5):621-31. PubMed ID: 20398809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Level of PAX5 in differential diagnosis of non-Hodgkin's lymphoma.
    Bharti B; Shukla S; Tripathi R; Mishra S; Kumar M; Pandey M; Mishra R
    Indian J Med Res; 2016 May; 143(Supplement):S23-S31. PubMed ID: 27748274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas.
    Krenacs L; Himmelmann AW; Quintanilla-Martinez L; Fest T; Riva A; Wellmann A; Bagdi E; Kehrl JH; Jaffe ES; Raffeld M
    Blood; 1998 Aug; 92(4):1308-16. PubMed ID: 9694719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma.
    Oliveira CC; Maciel-Guerra H; Kucko L; Hirama EJ; Brilhante AD; Quevedo FC; da Cunha IW; Soares FA; Niero-Melo L; Dos Reis PP; Domingues MA
    Diagn Pathol; 2017 Jan; 12(1):3. PubMed ID: 28061782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas.
    Dogan A; Bagdi E; Munson P; Isaacson PG
    Am J Surg Pathol; 2000 Jun; 24(6):846-52. PubMed ID: 10843287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker.
    Torlakovic E; Torlakovic G; Nguyen PL; Brunning RD; Delabie J
    Am J Surg Pathol; 2002 Oct; 26(10):1343-50. PubMed ID: 12360049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma.
    Chaganti SR; Chen W; Parsa N; Offit K; Louie DC; Dalla-Favera R; Chaganti RS
    Genes Chromosomes Cancer; 1998 Dec; 23(4):323-7. PubMed ID: 9824205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of p53 expression in malignant lymphomas.
    Said JW; Barrera R; Shintaku IP; Nakamura H; Koeffler HP
    Am J Pathol; 1992 Dec; 141(6):1343-8. PubMed ID: 1466398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
    Franco R; Scognamiglio G; Valentino E; Vitiello M; Luciano A; Palma G; Arra C; La Mantia E; Panico L; Tenneriello V; Pinto A; Frigeri F; Capobianco G; Botti G; Cerchia L; De Chiara A; Fedele M
    Oncotarget; 2016 Sep; 7(37):59158-59172. PubMed ID: 27494852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of PAX8 in comparison with PAX5 immunohistochemical staining in the diagnosis of Hodgkin lymphoma.
    Ameli F; Zahavi Z; Kosari F; Soleimani V
    Ann Diagn Pathol; 2022 Oct; 60():151974. PubMed ID: 35926290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.